x
Ariana Pharma
[contact-form-7 404 "Not Found"]

Ariana Pharma
  • Contact Us
  • Home
  • About Us
  • Our Business
  • Our Technology
  • Real World Data
  • News & more
    • In The News
    • Case study
    • Publications
      • Publications & Conferences
      • Whitepaper & blog
  • Careers
Logo

Contact Info

  • 58-60 Avenue de la Grande Armée, 75017, Paris, France
  • +33 1 44 37 17 00
  • info@arianapharma.com

Nov2023

ESMO 2023: Advances in the fight against cancer through artificial intelligence.

The collaboration between Ariana Pharma, Omicure, and the Léon Bérard Center has led to a breakthrough in identifying survival biomarkers across various cancer types using eXplainable Artificial Intelligence.

In a study, presented at ESMO 2023 [Identification of biomarkers of survival across multiple cancer types using eXplainable Artificial Intelligence], KEM®, a proprietary Ariana Pharma technology, was used to systematically explore association rules in the PROFILER cohort.

The list of candidate biomarkers included drug scores generated by OncoKEM, an AI-transcriptional-based therapeutic recommendation-tool that computes scores for up to 205 drugs based on the drug’s transcriptional signatures and the tumor transcriptional profile. The goal was to demonstrate the biological relevance of OncoKEM® by confronting its results with the findings obtained through a standard pathway analysis.

The analysis identified four pathway dysregulations associated with overall survival, three of which were related to tubulin. Consistently, four OncoKEM® scores were associated with survival, all of which corresponded to microtubule inhibitor drugs: ixabepilone, cabazitaxel, vinflunine, and brentuximab vedotin. The findings demonstrated the biological relevance of OncoKEM® for microtubule inhibitor drugs and paved the way for its use as a prognostic marker for refractory cancers.

 

Article
Poster
Abstract

Non-small cell lung cancer: Artificial intelligence enables the identification of survival signatures complementary to an Immunologically active gene expression signature involving previous therapies

In a subsequent study presented at ESMO 2023 [Non-small cell lung cancer: Artificial Intelligence enables the preliminary identification of complementary survival signatures that involve previous therapies] KEM Biomarker (IP software from Ariana) was used to increase the performance of the models previously found. The study identified two 4-gene signatures that predict survival with a significant interaction between the number of treatment lines and gene expressions. Patients carrying these signatures and having undergone at least two treatment lines showed improved survival in both models

 

Article
Poster
Abstract

Categories

  • Alzheimer's
  • Autism
  • Autoimmune disease
  • Cancer
  • Fibromyalgia
  • Kidney Transplant
  • Parkinson’s
  • Precision Medicine
  • Publications
  • Real World Evidence
  • Recent Posts
  • Type A Diabetes

Tags

alzheimer's autism cancer Event Fibromyalgia Graft rejection Influenza Kidney Laboratory lung neurological Oncology Professor Jean-Yves BLAY Centre Leon berard Parkinson Parkinson’s precisionmedicine precision medicine publication realworldevidence recent post Recent Posts Research Transplant vaccine

Ariana Pharmaceuticals, The AI DRUG Development Company

  • Paris, FRANCE / Cambridge, MA, USA
  • Call Us: +33 144 37 17 00
  • info@arianapharma.com

Menu

  • About Us
  • Our business
  • Technology
  • In The News
  • Contact Us

Subscribe

Keep in touch and subscribe to our latest news

    Ariana Pharma © 2024 All Rights Reserved